Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer

Journal of Nippon Medical School

Volumn 81, Issue 4, 2014, Pages 211-220

  Miura, Daishu ^a,b   Yoneyama, Kimiyasu ^c   Furuhata, Yoshiaki ^d   Shimizu, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Antibody dependent cell mediated cytotoxicity; Fc receptors; Human epidermal growth factor receptor 2; Natural killer cells; Trastuzumab

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOADING DRUG DOSE; MONOTHERAPY; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; TUMOR GROWTH; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MONOCYTE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MONOCYTES; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 84905725732     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.81.211     Document Type: Article

References (26)

1. Perez EA, Suman VJ, Davidson NE, et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29: 4491-4497.
2. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2―positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
3. Slamon D, Eiermann W, Robert N, et al.: Adjuvant trastuzumab in HER2―positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
4. Arnould L, Gelly M, Penault―Llorca F, et al.: Trastuzumab―based treatment of HER2―positive breast cancer: an antibody―dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-267.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446.
6. Cooley S, Burns LJ, Repka T, Miller JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody―dependent cellular cytotoxicity against LFA―3 and HER2/neu. Exp Hematol 1999; 27: 1533-1541.
7. Pohlmann PR, Mayer IA, Mernaugh R: Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15: 7479-7491.
8. Mohsin SK, Weiss HL, Gutierrez MC, et al.: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23: 2460-2468.
9. Kute T, Stehle Jr. JR, Ornelles D, Walker N, Delbono O, Vaughn JP: Understanding key assay parameters that affect measurements of trastuzumab―mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1: 810-821.
10. Stockmeyer B, Elsasser D, Dechant M, et al.: Mechanisms of G―CSF― or GM―CSF―stimulated tumor cell killing by Fc receptor―directed bispecific antibodies. J Immunol Methods 2001; 248: 103-111.
11. Collins DM,O’Donovan N, McGowan PM,O’Sullivan F, Duffy MJ, Crown J: Trastuzumab induces antibody―dependent cell―mediated cytotoxicity (ADCC) in HER―2―non―amplified breast cancer cell lines. Ann Oncol 2012; 23: 1788-1795.
12. Gennari R, Menard S, Fagnoni F, et al.: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655.
13. Repka T, Chiorean EG, Gay J, et al.: Trastuzumab and interleukin―2 in HER2―positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9: 2440-2446.
14. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87: 21-27.
15. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-69.
16. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c―erbB―2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-469.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-182.
18. Mieda J, Ohaki Y, Oguro T, et al.: Breast cancer with neuroendocrine differentiation detected by unique staining pattern of neoplastic cells in hercep test. J Nippon Med Sch 2004; 71: 203-208.
19. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER―2/neu proto―oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
20. Perez EA, Romond EH, Suman VJ, et al.: Four―year follow―up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2―positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B31. J Clin Oncol 2011; 29: 3366-3373.
21. Beano A, Signorino E, Evangelista A, et al.: Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008; 6: 25.
22. Kaur A, Dasanu CA: Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: Is paclitaxel involved? J Oncol Pharm Pract 2013; 19: 82-85.
23. Mozaffari F, Lindemalm C, Choudhury A, et al.: NKcell and T―cell functions in patients with breast cancer: effects of surgery and adjuvant chemo― and radiotherapy. Br J Cancer 2007; 97: 105-111.
24. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
25. Spiridon CI, Guinn S, Vitetta ES: A comparison of the in vitro and in vivo activities of IgG and F(ab’)2 fragments of a mixture of three monoclonal anti―Her2 antibodies. Clin Cancer Res 2004; 10: 3542-3551.
26. Varchetta S, Gibelli N, Oliviero B, et al.: Elements related to heterogeneity of antibody―dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67: 11991-11999.